On this page
NF2
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
The NF2 gene encodes merlin, a tumour suppressor protein that regulates cell growth and prevents uncontrolled division in the nervous system. NF2 provides instructions for producing merlin, also called schwannomin, a protein essential for controlling cell shape, growth, and adhesion in nervous system tissues.
NF2 is located on the long (q) arm of chromosome 22, at band 22q12.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 22 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The NF2 gene, located on chromosome 22, encodes a protein called merlin that functions as a crucial tumour suppressor in the nervous system. This protein is particularly abundant in Schwann cells, which form protective insulation around nerve fibres throughout the body. Merlin coordinates multiple cellular processes that prevent inappropriate cell division and maintain the organised structure of nervous tissue.
Pathogenic changes in NF2 lead to neurofibromatosis type 2, an inherited condition characterised by the development of multiple benign tumours affecting cranial and spinal nerves. The most recognisable feature of this disorder is bilateral vestibular schwannomas, tumours that grow on both auditory nerves connecting the inner ears to the brain. These growths can cause progressive hearing loss, balance problems, and other neurological complications. Beyond inherited forms, acquired changes in NF2 are also found in sporadic nervous system tumours across the general population.
The NF2 gene is classified as an ACMG Secondary Findings gene, meaning that laboratories performing genomic sequencing may report pathogenic variants even when testing was ordered for an unrelated reason. This classification reflects the gene's medical importance and the availability of interventions that can improve outcomes for individuals carrying disease-causing variants. Understanding NF2 function has provided insights into how cells normally regulate their growth boundaries and how loss of this control contributes to tumour development.
What the gene does
Merlin operates as a molecular scaffold that integrates signals from the cell membrane to control growth and division. The protein is predominantly expressed in nervous system tissues, where it fulfils critical roles in maintaining cellular architecture and preventing tumour formation. Merlin belongs to the ERM (ezrin-radixin-moesin) protein family, sharing structural features with these cytoskeletal regulators whilst possessing unique tumour suppressor capabilities that distinguish it from its relatives.
The protein functions by coordinating several major signalling pathways that govern cell behaviour. Merlin inhibits the Ras-Raf-MEK-ERK cascade, a pathway that normally promotes cell proliferation in response to growth signals. When merlin is present and active, it dampens this pathway's activity, preventing cells from receiving constant instructions to divide. The protein also modulates the Hippo signalling pathway, which controls organ size and tissue regeneration by regulating cell division and programmed cell death. Through these interactions, merlin ensures that cells divide only when appropriate signals are present and tissue growth is genuinely needed.
Merlin's tumour suppressor activity depends on its ability to shuttle between the cell membrane and the nucleus, responding to mechanical and biochemical cues from the cellular environment. At the membrane, the protein interacts with cell adhesion molecules and receptor tyrosine kinases, sensing whether cells are properly attached to neighbouring cells and the surrounding extracellular matrix. These adhesion contacts generate signals that merlin translates into growth control decisions. When cells lose contact with their neighbours or the supporting tissue structure, merlin typically activates growth-inhibitory signals, preventing cells from proliferating inappropriately in the absence of proper anchorage.
The protein also regulates cytoskeletal dynamics, influencing cell shape and movement. Merlin affects the organisation of actin filaments, the structural cables that give cells their form and enable them to migrate. By controlling cytoskeletal architecture, merlin influences how cells interact with their environment and whether they maintain appropriate tissue organisation. Loss of merlin function disrupts these regulatory mechanisms, allowing cells to ignore normal growth boundaries and proliferate without proper positional or contact cues.
Recent research indicates that merlin may also function within the nucleus, where it influences gene transcription programmes that control cell cycle progression. The protein appears to regulate which genes are turned on or off in response to growth signals, providing an additional layer of control over cellular proliferation. This nuclear role complements merlin's membrane-based functions, creating an integrated system that monitors both external signals and internal cell cycle checkpoints.
Video: Genetics 101
Chromosome location
NF2 resides on the long arm of chromosome 22 at position 22q12.2, a region that has been extensively mapped due to its clinical significance in tumour development. The gene spans approximately 110 kilobases of genomic DNA and contains 17 exons that encode the merlin protein. This chromosomal location is notable because chromosome 22 is one of the smaller human chromosomes and contains several other genes implicated in genetic disorders.
The 22q12 region is sometimes affected by larger chromosomal deletions that remove NF2 along with neighbouring genes, leading to more complex clinical presentations than isolated NF2 variants alone. The relatively compact structure of the gene, with moderately sized exons and introns, facilitates comprehensive genetic testing, allowing laboratories to sequence the entire coding region and splice junctions with standard methodologies. The chromosomal context of NF2 means that cytogenetic testing can sometimes identify large deletions involving this region, complementing DNA sequencing approaches for detecting smaller variants.
Protein structure
Merlin is a 595-amino-acid protein organised into several functional regions that enable its tumour suppressor activities. The N-terminal portion contains the FERM domain, spanning amino acids 22 to 311, which represents the most critical structural element of the protein. FERM domains are found across the ERM protein family and mediate interactions with membrane proteins, lipids, and signalling molecules. In merlin, the FERM domain binds to transmembrane receptors and adhesion molecules at the cell surface, positioning the protein to detect and respond to external growth signals.
The FERM domain comprises three subdomains that fold together to create a cloverleaf-shaped structure capable of recognising specific protein and lipid partners. This domain enables merlin to interact with receptor tyrosine kinases, cell adhesion molecules such as CD44, and membrane phospholipids, establishing the protein's role as a sensor of cell-surface events. Structural studies have revealed that the FERM domain can adopt different conformations depending on the protein's activation state, with intramolecular interactions regulating whether merlin is active or inactive as a growth suppressor.
The C-terminal region of merlin contains sequences that mediate protein-protein interactions and regulate the protein's subcellular localisation. This region includes binding sites for cytoskeletal components and signalling molecules that link merlin to downstream effector pathways. A distinctive feature of merlin compared with other ERM proteins is the C-terminal tail, which lacks the actin-binding domains found in ezrin, radixin, and moesin. Instead, merlin's C-terminus contains unique sequences that confer its specialised tumour suppressor functions.
Merlin activity is controlled by conformational changes that involve interaction between the N-terminal FERM domain and the C-terminal region. In the closed, active conformation, these two regions associate with each other, stabilising merlin in a growth-suppressive state. Phosphorylation events can disrupt this intramolecular interaction, causing merlin to adopt an open, inactive conformation that no longer effectively inhibits proliferation pathways. This regulatory mechanism allows cells to modulate merlin activity in response to growth signals and adhesion status, fine-tuning the balance between proliferation and growth arrest.
Key variants
Hundreds of pathogenic variants in NF2 have been documented in individuals with neurofibromatosis type 2, representing a broad spectrum of mutation types distributed across the gene's coding sequence. These variants include nonsense changes that introduce premature stop codons, frameshifts resulting from small insertions or deletions, splice-site alterations that disrupt normal mRNA processing, and missense substitutions that impair protein function. Large deletions encompassing multiple exons or the entire gene account for a subset of cases and typically correlate with more severe clinical presentations.
The functional consequences of NF2 variants typically involve complete loss of merlin protein or production of a non-functional truncated protein that cannot properly regulate cell growth pathways. Because merlin functions as a tumour suppressor, both copies of the gene must be inactivated for tumour development to occur, following Knudson's two-hit hypothesis. Individuals inherit one pathogenic variant in the germline, and tumours develop in cells that subsequently acquire a second variant affecting the remaining functional copy.
Genotype-phenotype correlations have emerged from studies of large patient cohorts, with certain variant types associated with more aggressive disease courses. Nonsense and frameshift variants that eliminate substantial portions of the protein, particularly those affecting the FERM domain, generally correlate with earlier onset of symptoms and greater tumour burden. Missense variants and splice-site changes may permit production of partially functional protein, sometimes resulting in milder presentations with later onset or fewer tumours. However, significant variability exists even among individuals carrying identical variants, indicating that additional genetic and environmental factors influence disease severity.
Mosaic NF2 variants, present in some but not all cells of the body, represent a distinct category that can produce segmental or localised disease manifestations. These individuals carry the variant only in a subset of tissues, leading to tumours restricted to particular body regions. Mosaicism can complicate genetic testing because the variant may be present at low levels in blood DNA or absent entirely, requiring analysis of tumour tissue to identify the causative change.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1006dup | p.Arg336fs | Pathogenic | ★★☆☆ | not provided |
c.1021C>T | p.Arg341Ter | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.10del | p.Ala4fs | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.1114G>T | p.Glu372Ter | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.111C>A | p.Cys37Ter | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.1165C>T | p.Gln389Ter | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.1219C>T | p.Gln407Ter | Pathogenic | ★★☆☆ | Neurofibromatosis, type 2 |
c.1228C>T | p.Gln410Ter | Pathogenic | ★★☆☆ | not provided |
c.1229dup | p.Arg411fs | Pathogenic | ★★☆☆ | Hereditary cancer-predisposing syndrome |
c.122G>A | p.Trp41Ter | Pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in NF2 cause neurofibromatosis type 2, an autosomal dominant disorder characterised by the development of multiple benign tumours throughout the nervous system. The hallmark feature is bilateral vestibular schwannomas, tumours arising from the nerve sheaths of both auditory nerves. These growths typically manifest in late adolescence or early adulthood, causing progressive hearing loss, tinnitus, and balance difficulties. As schwannomas enlarge, they can compress adjacent brain structures, leading to additional neurological complications.
Beyond vestibular schwannomas, individuals with neurofibromatosis type 2 frequently develop other nervous system tumours including meningiomas, which arise from the protective membranes surrounding the brain and spinal cord, and ependymomas, tumours originating from cells lining the fluid-filled spaces within the central nervous system. Peripheral schwannomas affecting nerves throughout the body are common, and some individuals develop spinal tumours that can cause pain, weakness, or sensory changes depending on their location. Ocular manifestations occur in many cases, including juvenile cataracts and retinal abnormalities that can affect vision.
The severity and progression of neurofibromatosis type 2 vary considerably among affected individuals, even within the same family. Some people experience rapid tumour growth and significant neurological complications requiring multiple surgical interventions, whilst others have slower disease progression with fewer tumours and milder symptoms. Management typically involves regular imaging surveillance to monitor tumour growth, surgical removal of symptomatic tumours, and occasionally targeted medical therapies. Early detection through genetic testing and proactive monitoring can improve outcomes by enabling intervention before tumours cause irreversible damage.
Acquired NF2 variants also occur in sporadic schwannomas, meningiomas, and ependymomas in the general population, even in individuals without inherited predisposition. These somatic changes represent one of the most frequent genetic alterations found in nervous system tumours, highlighting merlin's fundamental role in preventing tumour formation across diverse cell types.
Inheritance pattern
Conditions caused by pathogenic NF2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service, NF2 appears on multiple clinical gene panels that guide testing for inherited tumour predisposition and related disorders. The gene holds green (high-evidence) status on the Adult Solid Tumours Cancer Susceptibility panel and the Childhood Solid Tumours Cancer Susceptibility panel, reflecting robust evidence linking NF2 variants to increased tumour risk across the lifespan. This classification ensures that individuals with personal or family histories suggestive of neurofibromatosis type 2 can access genetic testing through NHS pathways.
NF2 is included on the Familial Tumours of the Nervous System panel (R221) and the broader Familial Tumours Syndromes of the Central and Peripheral Nervous System panel, both designated green, which facilitate diagnosis for families affected by inherited nervous system tumour syndromes. The gene's presence on the Bilateral Congenital or Childhood Onset Cataracts panel (R31, green status) acknowledges that early-onset lens opacities can be a presenting feature of neurofibromatosis type 2, sometimes appearing before characteristic nervous system tumours develop.
Additionally, NF2 appears on panels addressing pigmentary and mosaic skin disorders (Pigmentary Skin Disorders R236 and Mosaic Skin Disorders R327, both green), recognising that cutaneous manifestations occasionally occur in neurofibromatosis type 2 and that mosaic variants can produce segmental skin changes alongside localised tumour development. The gene's inclusion across this range of panels reflects the diverse clinical presentations that can prompt genetic evaluation and ensures comprehensive testing approaches for individuals with complex or atypical features.
NF2's designation as an ACMG Secondary Findings gene means that UK laboratories performing genomic sequencing may report pathogenic variants discovered incidentally during testing for unrelated conditions, provided patients have not opted out of receiving such information. This practice aims to identify individuals at risk for neurofibromatosis type 2 who can benefit from surveillance and early intervention, even when the genetic test was requested for a different clinical indication.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research into environmental and lifestyle factors that might influence tumour development in individuals carrying NF2 variants remains limited, as neurofibromatosis type 2 is primarily driven by loss of merlin function rather than modifiable external exposures. Unlike some cancer predisposition syndromes where dietary factors or physical activity demonstrably affect risk, no specific lifestyle interventions have been conclusively shown to prevent tumour formation or slow progression in people with pathogenic NF2 variants. The biological mechanisms underlying schwannoma and meningioma development relate principally to loss of growth control at the cellular level, which occurs regardless of diet or exercise patterns.
General health maintenance remains important for overall wellbeing, and some research suggests that maintaining healthy body weight and engaging in regular physical activity may support immune function and cellular repair mechanisms across the population. However, these observations derive from general population studies rather than specific evidence in neurofibromatosis type 2 cohorts, and individuals should not interpret lifestyle modifications as preventative measures against tumour development. The primary approach to managing NF2-related tumour risk involves regular clinical surveillance with MRI imaging to detect tumours early and appropriate medical or surgical intervention when tumours become symptomatic.
Noise exposure has been examined as a potential factor influencing vestibular schwannoma growth, given that these tumours affect the auditory system. Whilst excessive noise can damage hearing through separate mechanisms, no strong evidence indicates that noise exposure accelerates tumour development in individuals carrying NF2 variants. Nonetheless, protecting hearing health through sensible noise management makes sense for anyone, particularly those already at risk for hearing loss due to vestibular schwannomas.
Individuals with neurofibromatosis type 2 benefit from coordinated care with specialists familiar with the condition, including neurologists, neurosurgeons, ophthalmologists, and audiologists. Regular monitoring enables detection of new tumours or growth of existing lesions, allowing for timely treatment decisions. Psychological support can also be valuable, as living with a hereditary tumour syndrome and managing its physical and emotional impacts presents ongoing challenges for affected individuals and their families.
Supplement considerations
No dietary supplements have been demonstrated through rigorous clinical trials to prevent tumour development or slow disease progression in individuals carrying pathogenic NF2 variants. The mechanisms driving schwannoma and meningioma formation involve specific loss of merlin-mediated growth control, and current evidence does not support the use of vitamins, minerals, or herbal products as preventative or therapeutic interventions for neurofibromatosis type 2. Whilst various supplements have been proposed based on theoretical considerations about cellular signalling or antioxidant activity, these hypotheses have not translated into proven clinical benefits.
Some individuals wonder whether antioxidant supplements such as vitamin E, vitamin C, or coenzyme Q10 might offer protection against tumour development by reducing oxidative stress. Although oxidative damage can contribute to certain types of cancer, the primary driver of neurofibromatosis type 2 is loss of functional merlin protein rather than cumulative oxidative injury. No controlled studies have shown that antioxidant supplementation reduces tumour burden or improves outcomes in people with NF2 variants, and individuals should not rely on supplements as a strategy for managing their condition.
Curcumin, resveratrol, and green tea extracts have been investigated in laboratory models for various anti-cancer properties, and some in vitro studies have explored their effects on schwannoma cells. However, these laboratory findings do not establish clinical efficacy in humans, and the concentrations required to produce effects in cell culture often far exceed what can be achieved through oral supplementation. Without evidence from well-designed clinical trials, these supplements cannot be recommended as interventions for neurofibromatosis type 2.
Individuals considering any form of supplementation should discuss their plans with their healthcare team, as some products can interact with medications or interfere with medical treatments. High-dose vitamins or herbal supplements may affect liver function, blood clotting, or other physiological processes, potentially complicating surgical procedures or other medical interventions. The most effective approach to managing NF2-related tumour risk remains regular clinical surveillance and evidence-based medical care rather than reliance on unproven dietary supplements.
Frequently asked questions
What is the difference between neurofibromatosis type 1 and neurofibromatosis type 2?
Despite similar names, neurofibromatosis type 1 and type 2 are distinct genetic conditions caused by variants in different genes. Neurofibromatosis type 1 results from variants in the NF1 gene and typically causes café-au-lait spots, cutaneous neurofibromas, and freckling, whilst neurofibromatosis type 2 stems from NF2 variants and primarily causes nervous system tumours, particularly bilateral vestibular schwannomas, with fewer skin manifestations.
Can someone have neurofibromatosis type 2 without a family history?
Yes, approximately half of neurofibromatosis type 2 cases arise from de novo variants, meaning the genetic change occurred spontaneously in the affected individual rather than being inherited from a parent. These individuals have no family history but can pass the variant to their children with a 50 per cent probability for each pregnancy.
How are vestibular schwannomas in neurofibromatosis type 2 monitored?
Regular MRI scans of the brain and internal auditory canals are used to monitor vestibular schwannomas, typically performed annually or at intervals determined by tumour growth rate and clinical symptoms. These imaging studies allow clinicians to track tumour size and inform decisions about timing of surgical intervention or other treatments such as stereotactic radiotherapy.
Is genetic testing recommended for all family members if someone has neurofibromatosis type 2?
Predictive genetic testing is typically offered to at-risk relatives of individuals with confirmed pathogenic NF2 variants, usually after genetic counselling to discuss the implications of testing. Identifying variant carriers enables early surveillance and intervention before tumours cause symptoms, whilst confirming non-carrier status can spare individuals from unnecessary monitoring.
What treatments are available for neurofibromatosis type 2?
Management of neurofibromatosis type 2 focuses on surveillance imaging, surgical removal of symptomatic tumours, and occasionally stereotactic radiotherapy for tumours in challenging locations. Emerging medical therapies targeting specific growth pathways show promise in clinical trials, and hearing preservation strategies including cochlear implants or auditory brainstem implants can help maintain auditory function when vestibular schwannomas affect hearing.
Do all pathogenic NF2 variants lead to the same severity of disease?
No, significant variability exists in disease severity even among individuals carrying the same pathogenic variant. Nonsense and frameshift variants generally correlate with more severe presentations, whilst certain missense changes may permit residual protein function and milder symptoms. However, additional genetic factors and chance events during tumour development contribute to the observed clinical heterogeneity.
References
- Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016. PMID: 25893302
- Schroeder RD, Angelo LS, Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014. PMID: 24393766
- Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS letters. 2014. PMID: 24726726
- Hadfield KD, Newman WG, Bowers NL. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. Journal of medical genetics. 2008. PMID: 18285426
- Ahronowitz I, Xin W, Kiely R. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Human mutation. 2007. PMID: 16983642
- MacCollin M, Willett C, Heinrich B. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology. 2003. PMID: 12821741